varsetatug masetecan ("Varseta-M") — FDA meeting
2026
FDA interactions are planned in 2026 with goal of aligning on the potential first registrational study for Varseta-M monotherapy in advanced CRC starting in 1H 2027.Source filing
CTMX biotech catalysts & pipeline
CYTOMX THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
varsetatug masetecan ("Varseta-M") — Interim data
Late 2026
o A Phase 1 data update is expected by the end of 2026 with a focus on dose selection for late phase development.Source filing
CX-801 — Initial data
H1 2027
Initial clinical data for CX-801 in combination with KEYTRUDA® in advanced melanoma is expected in the first half of 2027.Source filing
varsetatug masetecan ("Varseta-M") — Initial data
1H 2027
Initial clinical data is anticipated in 1H 2027.Source filing
varsetatug masetecan ("Varseta-M") — Conference presentation
2026
We plan to present additional Phase 1 Varseta-M data at a medical meeting in 2026 and aim to align with the FDA in 2026 on a potential registrational study designed for Varseta-M monotherapy in advanced late-line CRC.Source filing